Company Overview of Allergan USA, Inc.
Allergan USA, Inc. manufactures pharmaceutical products and medicines. It acquires, develops, and markets pharmaceuticals for patient wellness within the genito-urinary and women’s healthcare markets. The company offers SANCTURA, a treatment for over-active bladder; PRO-QUIN, a treatment for urinary tract infections; and ESTRASORB to treat various symptoms of menopause, as well as PROSED line of urinary analgesic-antiseptic products. Allergan USA, Inc. was formerly known as Esprit Pharma, Inc. As a result of its acquisition by Allergan, Inc., Esprit Pharma, Inc.'s name was changed. The company was incorporated in 2004 and is based in Irvine, California. Allergan USA, Inc. operates as a subsi...
2525 Dupont Drive
Irvine, CA 92612
Founded in 2004
Key Executives for Allergan USA, Inc.
Vice President and Chief Financial Officer
Compensation as of Fiscal Year 2016.
Allergan USA, Inc. Key Developments
Allergan and Adamas Settle with Amneal in NAMZARIC Patent Litigation
Sep 9 16
Allergan announced that Forest Laboratories, Forest Laboratories Holdings and Allergan USA, along with Adamas Pharmaceuticals have entered into a settlement agreement with Amneal Pharmaceuticals and Amneal Pharmaceuticals of New York. The settlement relates to a patent infringement litigation brought by Forest and Adamas in response to Amneal's abbreviated new drug application (ANDA) seeking approval to market generic versions of Allergan's NAMZARIC (memantine and donepezil hydrochlorides) extended-release, a once-daily, fixed-dose combination of memantine hydrochloride (a NMDA receptor antagonist) and donepezil hydrochloride (an acetylcholinesterase inhibitor, AChEI). It is Allergan's understanding that Amneal is the first applicant to file an ANDA containing a paragraph IV certification regarding NAMZARIC.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries